Preclinical evaluation of avutometinib and defactinib in high‐grade endometrioid endometrial cancer
Abstract Background High‐grade endometrial cancers (EAC) are aggressive tumors with a high risk of progression after treatment. As EAC may harbor mutations in the RAS/MAPK pathways, we evaluated the preclinical in vitro and in vivo efficacy of avutometinib, a RAF/MEK clamp, in combination with the f...
Saved in:
Main Authors: | Tobias Max Philipp Hartwich, Miranda Mansolf, Cem Demirkiran, Michelle Greenman, Stefania Bellone, Blair McNamara, Shuvro P. Nandi, Ludmil B. Alexandrov, Yang Yang‐Hartwich, Silvia Coma, Jonathan Pachter, Alessandro D. Santin |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2024-09-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.70210 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Interdependence of coagulation with immunotherapy and BRAF/MEK inhibitor therapy: results from a prospective study
by: Malte Beckmann, et al.
Published: (2024-11-01) -
An open-label study to determine the maximum tolerated dose of oral ESK-440 administered as a single agent in patients with advanced or metastatic solid tumors
by: Russell J. Schilder, et al.
Published: (2025-03-01) -
Impairment of cocaine-mediated behaviours in mice by clinically relevant Ras-ERK inhibitors
by: Alessandro Papale, et al.
Published: (2016-08-01) -
Therapeutic benefit of the dual ALK/FAK inhibitor ESK440 in ALK-driven neuroblastoma
by: Seema Chugh, et al.
Published: (2025-02-01) -
Rosavin exerts an antitumor role and inactivates the MAPK/ERK pathway in small-cell lung carcinoma in vitro
by: Liu Rui, et al.
Published: (2023-06-01)